Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has announced its participation in the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Ying Huang, Ph.D., will deliver company updates at the event in San Francisco on January 14, 2025, at 3:45 p.m. PT. The presentation will be accessible via live audio webcast through Legend's Investor Relations website section, with a replay available approximately 48 hours after the event.
Details
News Market Reaction – LEGN
The recorded move for LEGN in the trading session of this news was +0.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.
Investors and other interested parties can access the live audio webcast through the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at https://legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.